Side-by-side comparison of AI visibility scores, market position, and capabilities
Jacksonville FL banking and capital markets fintech (NYSE: FIS) ~$10.1B FY2024 revenue; Worldpay divested 2023, IBS/HORIZON core banking, FIS Accelerate transformation competing with Fiserv and Jack Henry.
Fidelity National Information Services, Inc. (FIS) is a Jacksonville, Florida-based financial technology company — publicly traded on the New York Stock Exchange (NYSE: FIS) as an S&P 500 Information Technology component — providing banking technology solutions, capital markets software, and treasury management systems to financial institutions, capital markets firms, and corporate treasuries through approximately 55,000 employees following the January 2023 divestiture of the Worldpay merchant acquiring business to private equity firm GTCR for $18.5 billion (selling 55% of Worldpay — the global payments processing business acquired by FIS for $43 billion in 2019 — to GTCR at a significant write-down from acquisition price). In fiscal year 2024, FIS reported revenues of approximately $10.1 billion (continuing revenue from Banking Solutions — core banking systems, payments processing for financial institutions, digital banking platforms — and Capital Market Solutions — asset management software, trading technology, treasury management), with CEO Stephanie Ferris (appointed CEO in January 2023 following the departure of Gary Norcross) executing the "FIS Accelerate" transformation plan to improve operational efficiency, grow recurring software revenue, and return capital to shareholders through dividends and share repurchases. FIS's remaining business (post-Worldpay) focuses on mission-critical software for banks and capital markets firms: IBS (International Banking System — core banking for large global banks), HORIZON (community bank core banking), TOTAL PLUS (credit union software), and capital markets post-trade processing for broker-dealers, asset managers, and treasury departments.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.